REGULATORY

MHLW to Incentivize Physicians to Use Biosimilars with New Premium

January 30, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Ministry of Health, Labor and Welfare (MHLW) plans to create a new premium under the medical fee schedule to incentivize biosimilar use at healthcare institutions, which could affect prescribing trends for self-injectable products including etanercept follow-ons. The plan was…

To read the full story

Chuikyo Issues Recommendation for 2020 Reimbursement Reform; Biosimilar Premium Set at 1,500 Yen per Month
February 10, 2020

REGULATORY

MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
LDP’s Patch League Urges Finance Minister to Continue Coverage, Support Prices
December 16, 2025

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…